A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors.Hongfeng Gou, Hu J, Xiuying XIAO et al.|Journal of Clinical Oncology|2026Cited by 0